New chelation therapies and emerging chelating drugs for the treatment of iron overload

Expert Opinion on Emerging Drugs

Volumn 11, Issue 1, 2006, Pages 1-5

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Deferasirox; Deferiprone (L1); Deferitrin; Deferoxamine; GT 56 252; ICL 670; Iron chelators; Iron overload; L1NA11; Thalassaemia

Indexed keywords

CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFERITRINE; DEFEROXAMINE; GT 56252; NEW DRUG; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ARTHRALGIA; BETA THALASSEMIA; BLOOD TRANSFUSION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; HIGH RISK PATIENT; HUMAN; IRON ABSORPTION; IRON BALANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; METABOLIC REGULATION; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL; THALASSEMIA; ZINC DEFICIENCY;

BETA-THALASSEMIA; BLOOD TRANSFUSION; CARBOXYLIC ACIDS; CLINICAL TRIALS; DEFEROXAMINE; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; THIAZOLES;

EID: 33645128026     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.1.1     Document Type: Review

References (20)

1. KONTOGHIORGHES GJ, ERACLEOUS E, ECONOMIDES CH, KOLNAGOU A: Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr. Med. Chem. (2005)12:2663-2681. A detailed description of the properties and effects of the new experimental iron-chelating drugs.
2. KONTOGHIORGHES GJ, NEOKLEOUS K, KOLNAGOU A: Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Drug Saf. (2003)26:553-584.
3. WORLD HEALTH ORGANISATION: Community control of hereditary anaemias. WHO Bull. (1983)61:63-80.
4. KYRIACOU K, MICHAELIDES Y, SENKUS R et al.: Ultrastructural pathology of the heart in patients with β-thalassaemia major. Ultastructural Pathology (2000) 24:75-81.
5. ANDERSON LJ, WESTWOOD MA, HOLDEN S et al.: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. (2004)127:348-355.
6. NIELSEN P, FISCHER R, ENGELHARDT R et al.: Liver iron stores in patients with secondary haemochromatosis under iron chelation therapy with deferoxamine or deferiprone. Br. J. Haematol. (1995)91:827-833
7. MODELL B, BERDOUKAS V: The clinical approach to thalassaemia. Grune and Stratton, London, UK (1984).
8. KEBERLE H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci. (1964) 119:758-768.
9. MODELL B, KHAN M, DARLISON M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet (2000) 355:2051-2052.
10. KONTOGHIORGHES GJ, ALDOURI MA, HOFFBRAND AV et al.: Effective chelation of iron in β-thalassaemia with the oral chelator 1, 2-dimethyl-3- hydroxypyrid-4-one. Br. Med. J. (1987) 295:1509-1512. The first clinical trial results showing the efficacy of deferiprone in the treatment of iron overload in thalassaemia patients.
11. ANDERSON LJ, WONKE B, PRESCOTT E et al.: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (2002) 360:516-520. The first MRI T2* study showing the superiority of deferiprone over deferoxamine in cardiac iron removal and function.
12. KONTOGHIORGHES GJ, SHEPPARD L: Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorg. Chim. Acta (1987)136:L11-L12. Simple, inexpensive one step synthesis of deferiprone that can be used to provide inexpensive chelation therapy for all thalassaemia patients in the developing countries.
13. ORIGA R, BINA P, AGUS A et al.: Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematotogica. (2005)90:1309-1314.
14. NISBET-BROWN E, OLIVIERI NF, GIARDINA PJ et al.: Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003)361:1597-1602. The first pharmacokinetic and iron balance studies of deferasirox in iron-loaded thalassaemia patients.
15. CAPPELINI MD: Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Prac. Res. Clin. Haematol. (2005) 18:289-298.
16. MARQUIS J, DAGHER R, BREEM et al.: Pharmacokinetic of GT56-252, a novel orally available iron chelator in rat, dog and monkey. Biomarkers Environment (2003) 6:7-9.
17. DONOVAN JM, PALMER PA, PLONE MA, WONKE B: The safety and pharmacokinetics of GT56-252, a novel orally available iron chelator. Ear. J. Clin. Invest. (2004) 34(Suppl. I):39.
18. KONTOGHIORGHES GJ, BARR J, NORTEYT P, SHEPPARD L: Selection of a new generation of orally active α-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Am. J. Haematol. (1993) 42:340-349.
19. HARMATZ P, GRADY RW, VICHINSKY E et al.: Phase Ib study of the safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02(CHF5140, GS460) in iron-loaded patients. Blood (2003)102:423.
20. DRAGSTEN PR, HALLAWAY PE, HANSON GJ et al.: First human studies with a high-molecular-weight iron chelator. J. Lab. Clin. Med. (2000)135:57-65.